These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 11970755)

  • 1. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors.
    Verheul HM; Pinedo HM
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S80-4. PubMed ID: 11970755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.
    Shibuya M
    J Biochem Mol Biol; 2006 Sep; 39(5):469-78. PubMed ID: 17002866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor (VEGF) inhibition--a critical review.
    Moreira IS; Fernandes PA; Ramos MJ
    Anticancer Agents Med Chem; 2007 Mar; 7(2):223-45. PubMed ID: 17348829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
    Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM
    Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xiaotan Sanjie decoction inhibits angiogenesis in gastric cancer through Interleukin-8-linked regulation of the vascular endothelial growth factor pathway.
    Shi J; Lu Y; Wei P
    J Ethnopharmacol; 2016 Aug; 189():230-7. PubMed ID: 27224240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
    Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
    Ellis LM; Takahashi Y; Liu W; Shaheen RM
    Oncologist; 2000; 5 Suppl 1():11-5. PubMed ID: 10804085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
    Schenone S; Bondavalli F; Botta M
    Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross talk between the cardiovascular and nervous systems: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development.
    Lazarovici P; Marcinkiewicz C; Lelkes PI
    Curr Pharm Des; 2006; 12(21):2609-22. PubMed ID: 16842161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.